Evidence map›Paper›PMID 40027263›Full record

ArticleMolecular therapy. Methods & clinical development2025

Cell-penetrating peptide-grafted AAV2 capsids for improved retinal delivery via intravitreal injection.

Jiang-Hui Wang, Mengtian Cui, Hao Liu, Peiyi Guo, Jackson McGowan, Shun-Yun Cheng, Dominic J Gessler, Jun Xie, Claudio Punzo, Phillip W L Tai and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Methods & clinical development, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Surgical Approaches to Retinal Gene Therapy: 2025 Update.Bioengineering (Basel, Switzerland) · 2025
    Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jiang-Hui WangHorae Gene Therapy Center, University of Massachusetts Medical School, Worcester, MA 01605, USA.
Mengtian CuiHorae Gene Therapy Center, University of Massachusetts Medical School, Worcester, MA 01605, USA.
Hao LiuHorae Gene Therapy Center, University of Massachusetts Medical School, Worcester, MA 01605, USA.
Peiyi GuoHorae Gene Therapy Center, University of Massachusetts Medical School, Worcester, MA 01605, USA.
Jackson McGowanHorae Gene Therapy Center, University of Massachusetts Medical School, Worcester, MA 01605, USA.
Shun-Yun ChengDepartment of Ophthalmology and Visual Sciences, University of Massachusetts Chan Medical School, Worcester, MA 01605, USA.
Dominic J GesslerHorae Gene Therapy Center, University of Massachusetts Medical School, Worcester, MA 01605, USA.
Jun XieHorae Gene Therapy Center, University of Massachusetts Medical School, Worcester, MA 01605, USA.
Claudio PunzoHorae Gene Therapy Center, University of Massachusetts Medical School, Worcester, MA 01605, USA.
Phillip W L TaiHorae Gene Therapy Center, University of Massachusetts Medical School, Worcester, MA 01605, USA.
Guangping GaoHorae Gene Therapy Center, University of Massachusetts Medical School, Worcester, MA 01605, USA.

Funding

Project 4: A permanent off-switch for AAVU19AI149646 · NIAID · UNIVERSITY OF FLORIDA · PI FARZAN, MICHAEL R. · 2020 to 2024
$14.0M
Viral Vector CoreP01HL131471 · NHLBI · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI FLOTTE, TERENCE R. · 2016 to 2020
$11.3M
Sustained antibody delivery for durable suppression of immunodeficiency virus replicationR01AI121135 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI David T Evans · 2015 to 2026
$6.9M
Oligodendrocyte-focused rAAV gene therapy strategies for Canavan disease and LeukodystrophiesR01NS076991 · NINDS · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI Guangping Gao · 2012 to 2026
$5.7M
Next Generation of Recombinant AAV Serotype Vectors for Gene TherapyR01HL097088 · NHLBI · UNIVERSITY OF FLORIDA · PI GAO, GUANGPING, HERZOG, ROLAND W. · 2010 to 2018
$5.4M
Develop combinatorial non-viral and viral CRISPR delivery for lung diseasesUH3HL147367 · NHLBI · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI ANDERSON, DANIEL G, GAO, GUANGPING · 2021 to 2022
$2.9M
Develop combinatorial non-viral and viral CRISPR delivery for lung diseasesUG3HL147367 · NHLBI · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI ANDERSON, DANIEL G, GAO, GUANGPING · 2018 to 2020
$2.7M
Fortilin, CTNNA3, and the HeartR01HL152723 · NHLBI · UNIVERSITY OF WASHINGTON · PI FUJISE, KEN · 2021 to 2024
$2.7M
NHLBI NIH HHS P01 HL131471NHLBI NIH HHS R01 HL097088NHLBI NIH HHS R01 HL152723NHLBI NIH HHS UG3 HL147367NHLBI NIH HHS UH3 HL147367NIAID NIH HHS R01 AI121135NIAID NIH HHS U19 AI149646NINDS NIH HHS R01 NS076991
6 · The paper itself

Abstract

Recombinant adeno-associated virus (rAAV) is a leading vector for retinal gene therapy due to its favorable safety profile demonstrated by the FDA-approved Luxturna for Leber congenital amaurosis. However, challenges with low transduction efficiency and immunogenicity, coupled with the invasiveness of subretinal injections, have driven efforts to engineer AAV capsids for minimally invasive intravitreal delivery. Intravitreal injections face the barrier of the inner limiting membrane (ILM), particularly with AAV2-based vectors. In this study, we displayed cell-penetrating peptides (CPPs) on AAV2 capsids to enhance retinal cell transduction via intravitreal injection. Through

Indexed as

AAV2capsid screeningcell-penetrating peptideintravitreal injectionphotoreceptor

Identifiers

PMID40027263
PMCPMC11872077

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.